U.S. Markets closed

This company just had the best new drug launch of all-time

CNBC: Talking Numbers

Gilead Sciences announced better-than-expected earnings Wednesday, pushing shares higher. The results were driven by the launch of its new hepatitis C drug Sovaldi, which brought in $2.3 billion. So is it time to prescribe Gilead to your portfolio?